Stay updated on Oral Oteseconazole for Recurrent Vaginal Candidiasis Clinical Trial
Sign up to get notified when there's something new on the Oral Oteseconazole for Recurrent Vaginal Candidiasis Clinical Trial page.

Latest updates to the Oral Oteseconazole for Recurrent Vaginal Candidiasis Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe record now presents details of the completed Phase 3 oteseconazole study for recurrent vulvovaginal candidiasis, including its design, eligibility criteria, locations, outcomes, and study documents, instead of an access-denied message.SummaryDifference50%

- Check15 days agoChange DetectedThe site footer revision changes from v3.7.2 to v3.8.0, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check22 days agoChange DetectedA site-wide notice announces that NIH content may use “Super Intelligence” (SI) in place of “Artificial Intelligence” (AI) during a transition.SummaryDifference1%

- Check29 days agoChange DetectedThe footer’s site revision identifier changed from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check36 days agoChange DetectedThe ClinicalTrials.gov footer revision label changed from v3.7.0 to v3.7.1. The page still displays a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check57 days agoChange DetectedThe study page now shows a new Revision: v3.7.0 tag, signaling an update to the record. Several older documents and items (e.g., Statistical Analysis Plan, Study Protocol, PDFs, and related metadata) were removed from the history on the page.SummaryDifference17%

Stay in the know with updates to Oral Oteseconazole for Recurrent Vaginal Candidiasis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Oral Oteseconazole for Recurrent Vaginal Candidiasis Clinical Trial page.